Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
National Health Research Institutes currently manages 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 5 actions are distributed among 5 distinct examiners, showing that each pending case is being handled by a different individual. The prosecution workload is spread across 3 distinct art units, indicating that the company's biotechnology research spans several specialized areas within the patent office. This distribution requires a strategy that can accommodate the specific nuances of multiple art units.
JASON PATRICK GROSS is the busiest examiner for the portfolio, currently responsible for 1 pending office action. Because each of the 5 pending actions is assigned to a unique examiner, no unique individual has a concentrated influence over the company's current prosecution. The involvement of 3 distinct art units suggests that while the technology area is focused on biotechnology, the specific applications are diverse enough to be classified into different examination groups. This lack of examiner overlap across the actions highlights a decentralized prosecution landscape.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (80%) |
| §103 only | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GROSS, JASON PATRICK | 1 | 64.0% | +43.3% |
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
| VASSELL, MEREDITH ABBOTT | 1 | 30.3% | +47.0% |
| BALLARD, KIMBERLY | 1 | 53.7% | +49.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18980664 | INTERACTIVE ORAL CAVITY PHOTOGRAPHY SYSTEM AND ARTIFICIAL INTELLIGENCE IMAGE RECOGNITION ORAL CAVITY CANCER | GROSS, JASON PATRICK | — |
| 18543232 | METHOD FOR SELECTING A DRUG CANDIDATE FOR TREATING OR PREVENTING OR DELAYING THE ONSET OR PROGRESSION OF AN AMYLOIDOGENIC DISEASE | STEELE, AMBER D | — |
| 18453435 | METHOD AND SYSTEM FOR ESTABLISHING DISEASE PREDICTION MODEL | VASSELL, MEREDITH ABBOTT | — |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18374326 | INHIBITORS OF POSITIVE STRAND RNA VIRUSES | VALLE, ERNESTO | 34d |
| 18980664 | INTERACTIVE ORAL CAVITY PHOTOGRAPHY SYSTEM AND ARTIFICIAL INTELLIGENCE IMAGE RECOGNITION ORAL CAVITY CANCER | GROSS, JASON PATRICK | — |
| 18453435 | METHOD AND SYSTEM FOR ESTABLISHING DISEASE PREDICTION MODEL | VASSELL, MEREDITH ABBOTT | — |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | — |
| Art Unit | Apps |
|---|---|
| 3797 | 1 |
| 1623 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18980664 | INTERACTIVE ORAL CAVITY PHOTOGRAPHY SYSTEM AND ARTIFICIAL INTELLIGENCE IMAGE RECOGNITION ORAL CAVITY CANCER | GROSS, JASON PATRICK | 3797 | §101§103§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18543232 | METHOD FOR SELECTING A DRUG CANDIDATE FOR TREATING OR PREVENTING OR DELAYING THE ONSET OR PROGRESSION OF AN AMYLOIDOGENIC DISEASE | STEELE, AMBER D | — | §101§102§103§112 | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18374326 | INHIBITORS OF POSITIVE STRAND RNA VIRUSES | VALLE, ERNESTO | 1623 | §103 | Final Rejection | 34d | Pending | Sep 28, 2023 |
| 18453435 | METHOD AND SYSTEM FOR ESTABLISHING DISEASE PREDICTION MODEL | VASSELL, MEREDITH ABBOTT | — | §101§103§112 | Non-Final OA | — | Pending | Aug 22, 2023 |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | 1675 | §101§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial